Clinical Trial Update: Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on combination therapies with adagrasib for advanced non-small cell lung cancer with KRAS G12C mutation; the study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Adagrasib (adagrasib)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Advanced NSCLC, Metastatic Lung Cancer | Phase 2 | Status: RECRUITING